Board of Directors

Alain Le Roch, Chairman of the Board

Alain founded the AES Laboratoire Groupe (AES Chemunex, Agrobio and Adiagene), in 1980. AES Laboratoire Groupe was a biotechnology industrial group specialized in the rapid control of bacterial contaminants and dedicated to the food, cosmetics, pharmaceutical and veterinary industries.
In 2011, Alain Le Roch sold AES Laboratoire to BioMérieux, which specializes in medical and industrial microbiological diagnostics and went on to found his own investment company, the Kreizig Group.

Catherine Boule

Investment Director at CapDecisif Management, representing FCPR CapDecisif 3
Ms. Catherine Boule serves as a Partner, Investment Director and Member of Management Board at CapDecisif Management SAS, G1J Ile-de-France SA, SCR, Cap Decisif I, SCR and CapDecisif II, FCPR. Ms. Boule serves as Observer of Gecko Biomedical SAS. She looks after investments in the health sector at the firm. Ms. Boule worked at the Curie Institute and also for a high tech incubator. She serves as a Director of Voluntis S.A, Nokad S.A. and Echosens and at Axess Vision Technology, EyeBrain, Innavirvax, Eviagenics, Physikron, VitamFero, Watchfrog and Eyevensys. She serves as member of the Supervisory Board of Voluntis. She served as a Director of Nanobiotix SA. Ms. Boule served as an Advisory Board Member at Nokad S.A. She holds an M.Sc. in Molecular Biology from Paris University and a Masters degree in Management of Biotechnologies. Ms. Boule also holds a DEA Postgraduate Diploma in Molecular Biology from University Paris-VI and Master in Management of Technological Innovation in Organic-Industries from INA Grignon/Reims Management School.

François-Xavier Desforges – CEO

François-Xavier is a seasoned executive with a large experience in the bio-photonics field. He started his career at Photonetics SA of which he managed the US Subsidiary until 2001. Back to France, he was named Development Director of the iXCore holding in which he participated to the growth of the iXMarine group of companies (500 employees, 100 m€ turnover). In 2008, he was appointed President of Genewave which he successfully merged with Mobidiag in 2013. After leaving Genewave in 2014, he held various positions until he joined Prestodiag as President in May 2016.

A former student of ENS Cachan, FX holds a Master degree in Optics and Signal Processing from Paris Sud University (1985) and a PhD in Electronics from the University of Limoges in 1989.

Celia Hart

Investment Director at CEA Investissement, representing Amorçage Technologique Investissement (ATI) fund
Celia has more than 15 years’ experience in the chemical and biotechnology sector. She received her PhD in protein engineering from Oxford University (UK). Celia then worked in the UK Biotechnology industry at Cambridge Antibody Technology (now Medimmune) where she was the Head of Lead Optimisation and led the R&D development of several therapeutic antibodies. Following an MBA at the Grenoble School of Business (France), she has been involved in assessing new business opportunities built on strong science at leading institutions (ESRF, CEA). She joined CEA Investissement (Grenoble), one of the leading seed investment funds in France, in 2005 and is now Investment Director in charge of the life science sector. She is often involved in setting up new companies working together with French innovation agencies (incubators, innovation clusters, technology transfer offices, etc.). She serves on the Board of several companies including Cytoo, Fermentalg, ImmunId and Eviagenics.

Thibaut Mercey, Founder

Thibaut is a serial entrepreneur in the field of biophotonics. Engineer in optics by background, he co-founded his first high-tech start-up in 2001 (GenOptics) and developed a SPRi system for biomolecular interaction monitoring. He coordinated technical improvements and was instrumental in GenOptics’ early growth, In 2003, Thibaut co-founded Dermoptics, which developed an innovative UVB lamp to treat some dermatological diseases like psoriasis and vitiligo. Dermoptics has been taken over by Quantel S.A. in 2005, in which he build various medical devices product, from origination to marketing.
In 2013, Thibaut was named among the 10 Best French Innovators Under 35 by MIT Technology Review. Thibaut holds a MSc from Institut d’Optique Graduate School (aka “SupOptique”, Palaiseau, France, 2000) and a MBA from London Business School with a major in Entrepreneurial Management (London, UK, 2010). Thibaut founded Prestodiag in March 2012.